Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Raptiva Side Effects Lawsuits | Side Effects: Serious Infections, Malignancies, Malignant Melanoma, Skin Cancer, Tumors, Lymphomas

Raptiva Side Effects May Result In Skin Cancer Lawsuits

Raptiva | Lawsuits, Lawyers | Side Effects: Serious infections, Malignancies, Malignant Melanoma, Skin Cancer, Tumors, Lymphomas

Raptiva (Generic: Efalizumab) is a humanized monoclonal antibody targeted toward the hyperproliferative pathology of psoriasis. As an immunosuppressive agent, Raptiva "has the ability to enhance the threat of infection and reactivate latent, chronic infections," the label cautions. Serious infections and malignancies reported in patients taking Rapitva include malignant melanoma and non-melanoma skin cancer, non-cutaneous solid tumors, and lymphomas.

On, July 20, 2005, the FDA announced a new warning on the Genentech psoriasis drug Raptiva (efalizumab) following reports of four cases of hemolytic anemia that were diagnosed four to six months after patients started on the monoclonal antibody. Two of the cases occurred during clinical trials of Raptiva, and the other two were reported as post-marketing events, according to the FDA.

In a "Dear Healthcare Provider" letter issued July 20, Genentech reported that in two severe cases, hemoglobin levels dropped to 6 and 7 g/dL. "A causal relationship between Raptiva and these events has not been established but cannot be excluded," the letter said.

The package insert for Raptiva was modified to include a warning to stop use of the drug should hemolytic anemia occur. In addition, the information sheet has been updated to include news of post marketing reports of necrotizing fasciitis, tuberculous pneumonia, bacterial sepsis with seeding of distant sites, severe pneumonia with neutropenia, and worsening of infections such as pneumonia despite antimicrobial therapy.

Legal Help For Victims Affected By Raptiva

If you or a loved one took Raptiva and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


RaptivaRSS Feed

Raptiva No Longer Available in Canada

Jun 18, 2009 | Parker Waichman LLP
Raptiva has been pulled from the market in  Canada because of its association with an often-fatal brain infection called progressive multifocal leukoencephalitis (PML). The suspension of Raptiva sales in Canada is part of a global withdrawal of the drug.Raptiva works by blocking the activation of certain immune cells called T cells, and the migration of those cells into the skin. However, by suppressing the body’s natural defense system, it can also increase the risk of serious...

Raptiva Pulled from U.S. Market Following PML Deaths

Apr 8, 2009 | Parker Waichman LLP
Raptiva, an injectable drug used to treat moderate to severe plaque psoriasis, is being withdrawn from the U.S. market.  According  to Genentech, Raptiva has been associated with progressive multifocal leukoencephalopathy (PML), a serious and almost always fatal brain infection caused by a virus.Raptiva was approved by the  U.S. Food & Drug Administration (FDA) in 2003.   Raptiva works by blocking the activation of certain immune cells called T cells, and the...

Raptiva Sales Suspension Recommended in Europe After Reports of Brain Infections

Feb 20, 2009 | Parker Waichman LLP
On the same day U.S. regulators warned that the psoriasis drug Raptiva had been linked to three fatal case of a rare brain infection, their counterparts in the European Union have recommended sales of the drug be suspended.  In a statement, advisers to the European Medicines Agency (EMEA)  said that in light of the deaths, Raptiva's benefits do not outweigh its risks.Raptiva is an injectable drug that was approved by the  U.S. Food & Drug Administration (FDA) in 2003 to treat...

Raptiva Linked to Deadly Brain Disease

Feb 19, 2009 | Parker Waichman LLP
U.S. health regulators warned today that the psoriasis drug Raptiva has been associated with three fatal cases of a brain infection known as progressive multifocal leukoencephalopathy, or PML. The Food & Drug Administration (FDA) also said it was aware of a possible fourth Raptiva patient who may have developed the deadly brain disease.Raptiva is an injectable drug that was approved by the FDA in 2003 to treat moderate to severe plaque psoriasis.  Raptiva works by blocking the...

Raptiva Gets Black Box Warning for PML, Other Opportunistic Infections

Oct 17, 2008 | Parker Waichman LLP
Labeling of the Psoriasis Drug Raptiva Will Now Bear a New Black Box Warning The labeling  of the psoriasis drug Raptiva will now bear a new black box warning about its association with the deadly brain disease progressive multifocal leukoencephalopathy, or PML, and other life threatening infections.  The Food & Drug Administration (FDA) ordered the black box  after receiving reports of serious infections - including at least one case of PML -  in some patients...

More Raptiva News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo